Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 9 de 9
1.
J Pediatr Gastroenterol Nutr ; 65(6): 652-657, 2017 12.
Article En | MEDLINE | ID: mdl-28968289

OBJECTIVES: Genetic studies in adults/adolescent patients with chronic pancreatitis (CP) identified chymotrypsinogen C (CTRC) genetic variants but their association with CP risk has been difficult to replicate. To evaluate the risk of CP associated with CTRC variants in CP pediatric patients-control study. METHODS: The distribution of CTRC variants in CP pediatric cohort (n = 136, median age at CP onset 8 years) with no history of alcohol/smoking abuse was compared with controls (n = 401, median age 45). RESULTS: We showed that p.Arg254Trp (4.6%) and p.Lys247_Arg254del (5.3%) heterozygous mutations are frequent and significantly associated with CP risk in pediatric patients (odds ratio [OR] = 19.1; 95% CI 2.8-160; P = 0.001 and OR = 5.5; 95% CI 1.6-19.4; P = 0.001, respectively). For the first time, we demonstrated that the c.180TT genotype of common p.Gly60Gly variant is strong, an independent CP risk factor (OR = 23; 95% CI 7.7-70; P < 0.001) with effect size comparable to p.Arg254Trp mutation. The other novel observation is that common c.493+51C>A variant, both CA and AA genotype, is significantly underrepresented in CP compared with controls (15% vs 35%; OR = 0.33; 95% CI 0.19-0.59; P < 0.001 and 2.8% vs 11%; OR = 0.24; 95% CI 0.06-0.85; P = 0.027, respectively). CONCLUSIONS: Our study provides evidence that CTRC variants, including c.180TT (p.Gly60Gly) are strong CP risk factors. The c.493+51C>A variant may play a protective role against CP development.


Chymotrypsinogen/genetics , Genetic Predisposition to Disease , Pancreatitis, Chronic/genetics , Serine Endopeptidases/genetics , Adult , Child , Female , Genetic Variation , Genotype , Humans , Male , Pancreatitis, Chronic/diagnosis , Risk Factors , Trypsin Inhibitor, Kazal Pancreatic/genetics
4.
Dev Period Med ; 20(3): 222-227, 2016.
Article En | MEDLINE | ID: mdl-27941193

INTRODUCTION: Chronic pancreatitis (CP) in children is still a rare, although increasingly recognized entity. Over the duration of the disease several complications can be observed, two of which are major ones: endo- and exocrine insufficiency. In the medical care of children with CP it is crucial to diagnose the decreased endo- and exocrine function of the pancreas, in order to preserve patients from malnutrition and the failure to thrive. The aim of the study was to compare the usefulness of two indirect methods of assessing the pancreas exocrine function in children with CP. MATERIAL AND METHODS: Ninety one patients with CP were enrolled in the study (41 boys, 50 girls, aged 2-17.8 years). Only Patients who had had both the 72-hour fecal fat quantification and the 13C-mixed triglyceride breath test (13C -MTBT) performed were selected. We compared the results of both tests for sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in detecting exocrine pancreatic insufficiency. RESULTS: Out of 91 patients, 12 were diagnosed with exocrine pancreatic insufficiency (EPI). The sensitivity of the fecal fat quantification was 50%, the specificity for the test was 100%. PPV and NPV were 100% and 93%, respectively. 13C-MTBT had the sensitivity of 42% and the specificity of 99%. PPV and NPV for the breath test were of 83% and 92%, respectively. No statistically significant discrepancy between the values obtained was found. CONCLUSIONS: Although the 72-hour fecal fat quantification remains the gold standard in detecting EPI, both of the methods that had been investigated were shown to be comparable regarding sensitivity, specificity, PPV and NPV in assessing pancreas exocrine sufficiency in children with CP. Due to the easier execution of the breath test, both for the patient and for medical personnel, its importance may increase.


Breath Tests/methods , Exocrine Pancreatic Insufficiency/diagnosis , Feces/chemistry , Pancreatitis, Chronic/diagnosis , Adolescent , Child , Child, Preschool , Exocrine Pancreatic Insufficiency/metabolism , Female , Humans , Infant , Male , Pancreatic Function Tests/methods , Pancreatitis, Chronic/metabolism , Reference Values
5.
J Pediatr Gastroenterol Nutr ; 63(6): 665-670, 2016 12.
Article En | MEDLINE | ID: mdl-27673710

OBJECTIVES: The etiological factors of chronic pancreatitis (CP) in children differ from those in adults. To date, no study has assessed the clinical course of CP in young children. The aim of our study was to evaluate the etiology and the clinical presentation of the disease in children with disease onset before 5 years of age in comparison to later-onset of CP. METHODS: A total of 276 children with CP, hospitalized from 1988 to 2015, were enrolled in the study. Data on presentation, diagnostic findings, and treatment were reviewed. Two hundred sixty patients were screened for the most frequent mutations in major pancreatitis-associated genes, such as cationic trypsinogen/serine protease gene (PRSS1), serine protease inhibitor, Kazal type 1 gene (SPINK1), and cystic fibrosis transmembrane conductance regulator gene (CFTR). RESULTS: The disease onset before the age of 5 years occurred in 51 patients (group 1), the later onset in 225 patients (group 2). We found no significant discrepancies in distribution of the etiological factors between groups. The youngest patients (group 1) had more pancreatitis episodes (median 5.0 vs 3.00; P < 0.05) and underwent surgeries more frequently (25.5% vs 8.9%; P < 0.05). It could be associated with significantly longer follow-up in early onset group (median 6 vs 4 years; P < 0.05). There were no differences in nutritional status or exocrine and endocrine pancreatic function. CONCLUSIONS: Early- and later-onset pancreatitis have similar etiological factors with predominance of gene mutations. The most frequent mutation found was p.Asn34Ser (N34S) in SPINK1 gene. The clinical presentation differed in number of pancreatitis episodes and frequency of surgeries.


Age of Onset , Pancreatitis, Chronic/physiopathology , Adolescent , Child , Child, Preschool , Female , Genetic Predisposition to Disease , Humans , Infant , Longitudinal Studies , Male , Mutation , Pancreatitis, Chronic/etiology , Pancreatitis, Chronic/genetics , Risk Factors
6.
Pancreatology ; 16(4): 535-41, 2016.
Article En | MEDLINE | ID: mdl-27179762

BACKGROUND: Available data from adult patients do not reflect natural course of hereditary pancreatitis (HP) in children. To date, no study has assessed the clinical course of HP in children. OBJECTIVE: To investigate the clinical course of HP in children and compare it to non-HP group with chronic pancreatitis (CP). METHODS: A group of 265 children with CP, hospitalized from 1988 to 2014, were enrolled in the study. Medical records of those patients were reviewed for data on presentation, diagnostic findings and treatment. All children were screened for mutations in major pancreatitis-associated genes, i.e. PRSS1, SPINK1, and CFTR. RESULTS: HP was diagnosed in 41 children (15.5%). Family history was positive in 88% of children with HP. Mutations of PRSS1 gene were found in 80% (33/41) of HP patients. We detected p.R122H, p.R122C, p.N29I, and p.E79K mutation in 34% (14/41), 27% (11/41), 12% (5/41), and 7% (3/41) of HP patients, respectively. Patients with paternal inheritance had first symptoms earlier than those with maternal inheritance (5.9 vs. 9.1 years; P < 0.05). Children with HP showed more severe changes in ERCP then those from non-HP group (2.05 Cambridge grade, vs. 1.6°; P < 0.05). ESWL was performed more frequently in HP group (12.2% vs. 3.1%; P < 0.05). There was no difference in age of disease onset (7.98 vs. 8.9 years; NS), pancreatic duct stenting (46.3% vs. 33%; NS), or number of surgical interventions (12.2% vs. 14.3%; NS) between both groups. CONCLUSIONS: Children with HP reveal significantly more severe clinical presentation of the disease than non-HP patients, despite the same age of onset.


Pancreatitis/genetics , Pancreatitis/pathology , Adolescent , Age of Onset , Body Mass Index , Carrier Proteins/genetics , Child , Child, Preschool , Cohort Studies , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Disease Progression , Exons , Female , Genetic Predisposition to Disease , Humans , Infant , Male , Mutation/genetics , Pancreatic Ducts/pathology , Pancreatitis, Chronic/genetics , Pancreatitis, Chronic/pathology , Polymorphism, Restriction Fragment Length , Retrospective Studies , Trypsin/genetics , Trypsin Inhibitor, Kazal Pancreatic , Young Adult
7.
Pancreas ; 45(8): 1115-9, 2016 09.
Article En | MEDLINE | ID: mdl-27101572

OBJECTIVES: To evaluate the diagnostic accuracy of magnetic resonance cholangiopancreatography (MRCP) in the detection of chronic pancreatitis (CP)-specific changes in the pediatric population. METHODS: The study included 48 children with pancreatic disorders subjected to both endoscopic retrograde cholangiopancreatography (ERCP) and MRCP within a 1- to 4-month interval. The sensitivity, specificity, positive predictive value, and negative predictive value of MRCP in the detection of CP-specific changes were determined using ERCP as a diagnostic standard. RESULTS: Diagnostic ERCP pancreatograms were obtained in 41 (85.4%) of 48 patients and diagnostic MRCP images in all 48 children. The sensitivity and positive predictive value of MRCP were 77.1% and 90%, respectively, and its specificity and negative predictive value amounted to 50% and 27.3%, respectively. The patients with consistent results of MRCP and ERCP (ie, true-positive and true-negative cases) and individuals with incompatible results of the tests (ie, false-positive and false-negative cases) differed in terms of their median age at MRCP (14.17 vs 10.33 years) and median CP stage according to the Cambridge Scale (4 vs 2). CONCLUSIONS: Magnetic resonance cholangiopancreatography provides diagnostic information equivalent to ERCP in a large percentage of pediatric patients with CP and should be used as the imaging method of choice, especially if the likelihood of therapeutic intervention is low.


Pancreatitis, Chronic , Child , Cholangiopancreatography, Endoscopic Retrograde , Cholangiopancreatography, Magnetic Resonance , Humans
9.
Dev Period Med ; 20(4): 279-286, 2016.
Article En | MEDLINE | ID: mdl-28216481

Autoimmune pancreatitis (AIP) is a rare chronic inflammatory autoimmune disease of the pancreas. It is estimated that it accounts for 2-6% of all the chronic pancreatitis (CP) cases in adult patients. AIP is usually characterized by sudden onset. The presenting symptoms most commonly include painless jaundice, general weakness and loss of weight. Imaging studies often reveal diffuse enlargement or focal changes of pancreatic parenchyma. In view of the clinical manifestation and changes documented on imaging, AIP should be considered after performing a differential diagnosis from pancreatic cancer or inflammatory masses in the course of CP. According to the International Consensus Diagnostic Criteria (ICDC), AIP can be sub-classified into two subtypes. Type 1 AIP is seen mainly in adult patients and characterized by elevated serum IgG4 levels and its association with IgG4-related disease at extrapancreatic sites (eg, sialadenitis, retroperitoneal fibrosis). Type 2 AIP presents in younger individuals. Serological abnormalities are usually absent. There are no systemic manifestations, except for inflammatory bowel disease. Histologically, type 1 AIP is characterized by massive infiltration by IgG4-positive plasma cells, whereas type 2 AIP shows neutrophilic infiltration with granulocytic epithelial lesions (GELs). Both types rapidly respond to steroid therapy. AIP is extremely rare in children. So far about twenty-five case reports of paediatric AIP were described. Due to such an infrequent occurrence, paediatricians may be unfamiliar with the optimal diagnostic and management strategies of this condition.


Pancreatitis, Chronic/pathology , Adolescent , Autoimmune Diseases , Child , Diagnosis, Differential , Female , Humans , Male , Pancreatitis, Chronic/diagnosis , Pancreatitis, Chronic/drug therapy , Steroids/therapeutic use
...